Zobrazeno 1 - 10
of 20
pro vyhledávání: ''
Autor:
Alexander Stein, Lisa Paschold, Joseph Tintelnot, Eray Goekkurt, Svenja-Sibylla Henkes, Donjete Simnica, Christoph Schultheiss, Edith Willscher, Marcus Bauer, Claudia Wickenhauser, Peter Thuss-Patience, Sylvie Lorenzen, Thomas Ettrich, Jorge Riera-Knorrenschild, Lutz Jacobasch, Albrecht Kretzschmar, Stefan Kubicka, Salah-Eddin Al-Batran, Anke Reinacher-Schick, Daniel Pink, Marianne Sinn, Udo Lindig, Wolfgang Hiegl, Axel Hinke, Susanna Hegewisch-Becker, Mascha Binder
Publikováno v:
JAMA Oncology.
In metastatic esophagogastric adenocarcinoma (EGA), the addition of programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in selected patient populations.To investigate the efficacy of trastuzumab and PD-1 inhibitors with cy
Autor:
Matthew H. G. Katz, Qian Shi, Jeff Meyers, Joseph M. Herman, Michael Chuong, Brian M. Wolpin, Syed Ahmad, Robert Marsh, Larry Schwartz, Spencer Behr, Wendy L. Frankel, Eric Collisson, James Leenstra, Terence M. Williams, Gina Vaccaro, Alan Venook, Jeffrey A. Meyerhardt, Eileen M. O’Reilly
Publikováno v:
JAMA Oncology. 8:1263
ImportanceNational guidelines endorse treatment with neoadjuvant therapy for borderline resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy remains unclear.ObjectiveTo compare treatment with neoadjuvant modified FOLFIRINOX (m
Autor:
Kelly Mousa, Keyur Mehta, Marcus Schmidt, Beate Rautenberg, Tessa Dibble, R. Charles Coombes, Robert Grieve, Janine Mansi, Holly Tovey, John M. S. Bartlett, Uwe Rhein, Carlo Palmieri, Elisabeth Murray, Lucy Kilburn, Sibylle Loibl, Abigail Evans, Andreas Makris, Robert E. Coleman, Annabel Borley, Catarina Alisa Kunze, Gunter von Minckwitz, Investigators, Judith M Bliss, Carsten Denkert, Jonathan Hicks, Xiao Lou Lu
Publikováno v:
JAMA Oncol
Importance Patients with breast cancer remain at risk of relapse after adjuvant therapy. Celecoxib has shown antitumor effects in preclinical models of human breast cancer, but clinical evidence is lacking. Objective To evaluate the role of celecoxib
Autor:
Keyur P. Patel, Prithviraj Bose, Nathan Fowler, Zeev Estrov, William Plunkett, Varsha Gandhi, Xuemei Wang, Marina Konopleva, Elias Jabbour, Michael J. Keating, Jan A. Burger, Nichole Cruz, Yesid Alvarado, Koichi Takahashi, Musa Yilmaz, Sa A. Wang, Wei Wang, Naveen Garg, Philip A. Thompson, Gautam Borthakur, Jeffrey L. Jorgensen, Naveen Pemmaraju, Ana Ayala, Chongjuan Wei, Maro Ohanian, Hagop M. Kantarjian, William G. Wierda, Rashmi Kanagal-Shamanna, Courtney D. DiNardo, Nitin Jain, Alessandra Ferrajoli, Tapan M. Kadia, Koji Sasaki
Publikováno v:
JAMA Oncol
Importance Oral targeted therapies have advanced the treatment of chronic lymphocytic leukemia (CLL). These therapies include Bruton tyrosine kinase inhibitors, used as monotherapy, and the Bcl-2 inhibitor venetoclax, typically combined with the CD20
Autor:
Nina A. Karaseva, Sukrut Shah, Lucjan Wyrwicz, Joseph Chao, Christian Caglevic, Kohei Shitara, Luis Villanueva, Eric Van Cutsem, Al B. Benson, Eray Goekkurt, Wasat Mansoor, Marcelo Garrido, Iveta Kudaba, Keun Wook Lee, Jeeyun Lee, Maria Alsina, Andrew H. Ko, Charles S. Fuchs, S. Peter Kang, Josep Tabernero, Hugo Castro, Hironaga Satake, Uma Kher, Yung-Jue Bang, Maria Ignez Braghiroli, Peter C. Enzinger, Zev A. Wainberg, Hyun Cheol Chung
Publikováno v:
JAMA Oncology. 6:1571
Importance Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. Objective To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alo
Autor:
Bruce Colwell, John R. Goffin, Hagen F. Kennecke, B. Samson, Félix Couture, Setareh Samimi, Tahir Abbas, Francine Aubin, Scott R. Berry, Alice C. Wei, Dongsheng Tu, Sheryl Koski, Nadine M Magoski, Petr Kavan, Chaudhary E. Ahmad, Jonathan M. Loree, Mohammed Harb, Christopher J. O'Callaghan, Nathalie Aucoin, Eric Chen, Derek J. Jonker
Publikováno v:
JAMA Oncology. 6:831
Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H).To evaluate whether combining programmed death-ligand 1 (P
Autor:
Nikolaus Schultz, Jeffrey A. Drebin, Kian-Huat Lim, William C. Chapman, Anna M. Varghese, Ryan C. Fields, M.B. Majella Doyle, Andrea Cercek, Thomas Boerner, Leonard B. Saltz, Peter J. Allen, Neeta Vachharajani, Diane Reidy-Lagunes, Michael I. D’Angelica, Haley Hauser, Taryn M. Boucher, Mithat Gonen, Steven M. Strasberg, Richard K. G. Do, Nancy E. Kemeny, Ronald P. DeMatteo, William G. Hawkins, William R. Jarnagin, Luis A. Diaz, T. Peter Kingham, Joanne F. Chou, Benjamin R. Tan, James J. Harding, Vinod P. Balachandran, Maeve A. Lowery, Francisco Sanchez-Vega
Publikováno v:
JAMA Oncol
Importance Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with a median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients. Objectiv
Autor:
Thierry Conroy, Eric Francois, Gael Deplanque, François Ghiringhelli, Christian Borel, Sandrine Hiret, Jean-François Seitz, Olivier Bouché, Trevor Stanbury, Jaafar Bennouna, Antoine Adenis, Aurélie Bertaut, Marc G. Denis, Mohamed Hebbar, Christophe Borg, Pascal Artru, Gaetan Des Guetz
Publikováno v:
JAMA Oncology. 5:83
IMPORTANCE: Second-line treatment with chemotherapy plus bevacizumab or cetuximab is a valid option for metastatic colorectal cancer. OBJECTIVE: To evaluate the progression-free survival (PFS) rate at 4 months with chemotherapy plus bevacizumab vs ce
Autor:
Cesare Gridelli, Yuichiro Ohe, Jaafar Bennouna, Ashis Das-Gupta, Nick Thatcher, Margarita Donica, Francesco Grossi, Matt Truman, Konstantinos N. Syrigos, Javier de Castro Carpeño, Frank Griesinger, Anne-Marie C. Dingemans, Corey J. Langer, Vlatka Smoljanovic
Publikováno v:
JAMA Oncology, 4(12):183486. American Medical Association
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Importance Bevacizumab treatment beyond progression has been investigated in breast and metastatic colorectal cancers. Avastin in All Lines Lung (AvaALL) is the first randomized phase 3 study of bevacizumab across multiple lines of treatment beyond p
Autor:
Tara Sanft, Wei Wei, Christos Hatzis, Lajos Pusztai, Tomoko Kurita, Borbála Székely, Kenneth R. Hess
Publikováno v:
JAMA Oncology. 4:e175092
Importance Many large adjuvant clinical trials end up underpowered because of fewer than expected events in the control arm. Ensuring a minimum number of events would result in more informative trials. Objective To calculate individualized residual r